Mesenchymal Stem Cell Therapy for Ex Vivo Repair of Ischemic Injury in Pig Donor Lungs

Nakajima, Daisuke; Watanabe, Y.; Ohsumi, Akihiro; Pipkin, M.; Chen, M.; Mordant, Pierre; Kanou, Takashi; Guan, Z.; Lam, Ryan; Coutinho, R.; Caldarone, Lindsay; Lyer, R.K.; Davies, John E.; Waddell, T.K.; Cypel, Marcelo; Liu, M.; Keshavjee, S.

doi:10.1016/j.healun.2017.01.167

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute lung injury and pro-inflammatory markers were also decreased in the MSC group. Air movement was also improved, as peak airway pressures were decreased in the MSC group compared to control as well [17]. It has been hypothesized that MAPCs can decreased primary graft dysfunction in transplanted organs by decreasing ischemic-perfusion injury.…”

Section: Stem-cell Therapymentioning

confidence: 91%

Uses of Ex-Vivo Lung Perfusion in Pulmonary Translational Medicine

Chan

2019

BJSTR

View full text Add to dashboard Cite

Section: Stem-cell Therapymentioning

confidence: 91%

Uses of Ex-Vivo Lung Perfusion in Pulmonary Translational Medicine

Chan

2019

BJSTR

View full text Add to dashboard Cite

“…In one large animal transplant study, swine lungs were perfused with human umbilical cord MSCs after 24 hours of static cold storage and an additional 12 hours of EVLP. Once transplanted and reperfused, lungs treated with MSCs had significantly reduced acute lung injury scores, improved wetto-dry ratios, lower levels of inflammatory cytokines, and higher levels of growth factors than the control group, suggesting an amelioration of IRI associated with the transplantation process (86). Previous studies from the same group confirmed that intravascular perfusion led to better retention of cells in the parenchyma than intrabronchial delivery of MSCs, and that larger numbers of cells perfused offered little benefit over the optimum dose of 5 million cells/kg (143,144).…”

Section: Msc Delivery Using Evlpmentioning

confidence: 92%

“…EVLP has been used for targeted delivery of immunosuppressive agents including perfusate-based methylprednisolone (80), intrabronchial adenoviral human IL-10 (81), and drugs targeting leukocyte activation and function (82,83). Further applications of EVLP involve modification of lung properties (84), anti-microbial treatment (85), and administration of cellular-based therapies (86)(87)(88)(89)(90)(91).…”

Section: Ex-vivo Lung Perfusionmentioning

confidence: 99%

Novel approaches for long-term lung transplant survival

Miller

Allan

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Allograft failure remains a major barrier in the field of lung transplantation and results primarily from acute and chronic rejection. To date, standard-of-care immunosuppressive regimens have proven unsuccessful in achieving acceptable long-term graft and patient survival. Recent insights into the unique immunologic properties of lung allografts provide an opportunity to develop more effective immunosuppressive strategies. Here we describe advances in our understanding of the mechanisms driving lung allograft rejection and highlight recent progress in the development of novel, lung-specific strategies aimed at promoting long-term allograft survival, including tolerance.

show abstract

“…Tumor necrosis factor-α and pathological acute lung injury score were significantly decreased in the MSC group compared with the control group. 59,60 Additionally, it has been hypothesized that MAPCs may decrease ischemic-reperfusion injury and, as a result, subsequent PGD. La Francesca et al utilized donor lungs that were not used for transplantation and stored them in cold storage for 8 hours.…”

Section: Stem Cell Therapymentioning

confidence: 99%

Ex Vivo Lung Perfusion: A Review of Research and Clinical Practices

Chan

Kumar

Subramaniam

et al. 2020

Semin Cardiothorac Vasc Anesth

View full text Add to dashboard Cite

End-stage lung disease is ultimately treated with lung transplantation. However, there is a paucity of organs with an increasing number of patients being diagnosed with end-stage lung disease. Ex vivo lung perfusion has emerged as a potential tool to assess the quality and to recondition marginal donor lungs prior to transplantation with the goal of increasing the donor pool. This technology has shown promise with similar results compared with the conventional technique of cold static preservation in terms of primary graft dysfunction and overall outcomes. This review provides an update on the results and uses of this technology. The review will also summarize clinical studies and techniques in reconditioning and assessing lungs on ex vivo lung perfusion. Last, we discuss how this technology can be applied to fields outside of transplantation such as thoracic oncology and bioengineering.

show abstract

Mesenchymal Stem Cell Therapy for Ex Vivo Repair of Ischemic Injury in Pig Donor Lungs

Cited by 3 publications

References 0 publications

Uses of Ex-Vivo Lung Perfusion in Pulmonary Translational Medicine

Uses of Ex-Vivo Lung Perfusion in Pulmonary Translational Medicine

Novel approaches for long-term lung transplant survival

Ex Vivo Lung Perfusion: A Review of Research and Clinical Practices

Contact Info

Product

Resources

About